Malignant Ovarian Tumors During Pregnancy: A Multicenter Retrospective Analysis

Liya Wang,1 Shenjiao Huang,2 Xiujie Sheng,3 Chenchen Ren,4 Qiming Wang,5 Linqing Yang,6 Shuping Zhao,7 Tianmin Xu,8 Xiaoxin Ma,9 Ruixia Guo,10 Pengming Sun,11 Yang Lin,8 Yuhong Li,1 Jiandong Wang,12 Yudong Wang1 1Department of Gynecologic Oncology, International Peace Maternity and Child Health Hosp...

Full description

Bibliographic Details
Main Authors: Wang L, Huang S, Sheng X, Ren C, Wang Q, Yang L, Zhao S, Xu T, Ma X, Guo R, Sun P, Lin Y, Li Y, Wang J, Wang Y
Format: Article
Language:English
Published: Dove Medical Press 2020-10-01
Series:Cancer Management and Research
Subjects:
Online Access:https://www.dovepress.com/malignant-ovarian-tumors-during-pregnancy-a-multicenter-retrospective--peer-reviewed-article-CMAR
id doaj-dfc320a9085b429dac79cef6b3d20b16
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Wang L
Huang S
Sheng X
Ren C
Wang Q
Yang L
Zhao S
Xu T
Ma X
Guo R
Sun P
Lin Y
Li Y
Wang J
Wang Y
spellingShingle Wang L
Huang S
Sheng X
Ren C
Wang Q
Yang L
Zhao S
Xu T
Ma X
Guo R
Sun P
Lin Y
Li Y
Wang J
Wang Y
Malignant Ovarian Tumors During Pregnancy: A Multicenter Retrospective Analysis
Cancer Management and Research
malignant ovarian tumor
pregnancy
management
prognosis
author_facet Wang L
Huang S
Sheng X
Ren C
Wang Q
Yang L
Zhao S
Xu T
Ma X
Guo R
Sun P
Lin Y
Li Y
Wang J
Wang Y
author_sort Wang L
title Malignant Ovarian Tumors During Pregnancy: A Multicenter Retrospective Analysis
title_short Malignant Ovarian Tumors During Pregnancy: A Multicenter Retrospective Analysis
title_full Malignant Ovarian Tumors During Pregnancy: A Multicenter Retrospective Analysis
title_fullStr Malignant Ovarian Tumors During Pregnancy: A Multicenter Retrospective Analysis
title_full_unstemmed Malignant Ovarian Tumors During Pregnancy: A Multicenter Retrospective Analysis
title_sort malignant ovarian tumors during pregnancy: a multicenter retrospective analysis
publisher Dove Medical Press
series Cancer Management and Research
issn 1179-1322
publishDate 2020-10-01
description Liya Wang,1 Shenjiao Huang,2 Xiujie Sheng,3 Chenchen Ren,4 Qiming Wang,5 Linqing Yang,6 Shuping Zhao,7 Tianmin Xu,8 Xiaoxin Ma,9 Ruixia Guo,10 Pengming Sun,11 Yang Lin,8 Yuhong Li,1 Jiandong Wang,12 Yudong Wang1 1Department of Gynecologic Oncology, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Municipal Key Clinical Specialty, Shanghai Key Laboratory of Embryo Original Disease, Shanghai, 200030, People’s Republic of China; 2Department of Obstetrics and Gynecology, Guangzhou Women and Children’s Medical Centre, Guangzhou 510623, People’s Republic of China; 3Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Major Obstetric Diseases of Guangdong Province, Guangzhou 510150, People’s Republic of China; 4Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People’s Republic of China; 5Department of Obstetrics and Gynecology, Women and Children’s Hospital of Ningbo City, Ningbo 315012, People’s Republic of China; 6Department of Gynecology, Affiliated Hospital of Jining Medical University, Jining 272029, People’s Republic of China; 7Department of Gynecology, Women and Children’s Hospital of Qingdao, Qingdao 266000, People’s Republic of China; 8Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun 130000, People’s Republic of China; 9Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated of China Medical University, Shenyang 110004, People’s Republic of China; 10Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People’s Republic of China; 11Department of Obstetrics and Gynecology, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou 350001, People’s Republic of China; 12Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, People’s Republic of ChinaCorrespondence: Yudong Wang Department of Gynecologic OncologyInternational Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, NO. 1961, Huashan Road, Shanghai 200030, People’s Republic of ChinaEmail gfywangyudong@126.comJiandong WangDepartment of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, NO. 251, Yao Jiayuan Road, Beijing 100026, People’s Republic of ChinaEmail wangjiandongxy@hotmail.comPurpose: The aim of this study was to investigate the clinical characteristics and management of malignant ovarian tumors during pregnancy, as well as the feto-maternal outcomes and analyze the influential factors on the pregnancy outcomes.Patients and Methods: Eighty-five patients with ovarian malignancies during pregnancy treated at 12 tertiary hospitals between 2009 and 2019 were analyzed in this study. The clinical features, histopathological characteristics, clinical management, and maternal and perinatal outcomes were retrospectively analyzed. The clinical features and managements were compared between abortion group and live birth group.Results: The following diagnoses were made: 41 (48.24%) patients with borderline ovarian tumors, 18 (21.18%) patients with epithelial ovarian cancers, 17 (20.00%) patients with non-epithelial ovarian malignancies and 9 (10.59%) patients with metastatic ovarian tumors. Thirty-six (42.45%) patients underwent conservative surgical treatment. Thirty-four (40.00%) patients opted for fertility-sparing surgery, and fifteen (17.56%) patients received radical surgery. Chemotherapy was administered to 32.94% of the patients. The proportion of ovarian malignancies diagnosed in the first trimester in the abortion group was higher than that in the live birth group (P< 0.05). However, tumor diameter, reproductive history, stage and surgical indications showed no significant differences between groups. A total of 67 live babies were recorded in this study, including 19 premature babies and 1 full-term newborn who died of respiratory distress. All of the BOTs were diagnosed with stage I, among whom 38 (92.68%) patients exhibited disease-free survival. Twenty-eight ovarian cancers were in stage I–II and 26 of them had disease-free survival with the longest follow-up time of 10 years. Five of the sixteen patients in advanced stage (stage III–IV) died, four of whom had metastatic tumors.Conclusion: Pregnant women with early-stage malignant ovarian tumors appear to have favorable outcomes. Conservative surgery is acceptable for early-stage borderline ovarian tumors during pregnancy. The gestational age of ovarian malignancy detection is key for pregnancy outcomes.Keywords: malignant ovarian tumor, pregnancy, management, prognosis
topic malignant ovarian tumor
pregnancy
management
prognosis
url https://www.dovepress.com/malignant-ovarian-tumors-during-pregnancy-a-multicenter-retrospective--peer-reviewed-article-CMAR
work_keys_str_mv AT wangl malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT huangs malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT shengx malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT renc malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT wangq malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT yangl malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT zhaos malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT xut malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT max malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT guor malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT sunp malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT liny malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT liy malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT wangj malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
AT wangy malignantovariantumorsduringpregnancyamulticenterretrospectiveanalysis
_version_ 1724870409877192704
spelling doaj-dfc320a9085b429dac79cef6b3d20b162020-11-25T02:20:42ZengDove Medical PressCancer Management and Research1179-13222020-10-01Volume 12108411084858711Malignant Ovarian Tumors During Pregnancy: A Multicenter Retrospective AnalysisWang LHuang SSheng XRen CWang QYang LZhao SXu TMa XGuo RSun PLin YLi YWang JWang YLiya Wang,1 Shenjiao Huang,2 Xiujie Sheng,3 Chenchen Ren,4 Qiming Wang,5 Linqing Yang,6 Shuping Zhao,7 Tianmin Xu,8 Xiaoxin Ma,9 Ruixia Guo,10 Pengming Sun,11 Yang Lin,8 Yuhong Li,1 Jiandong Wang,12 Yudong Wang1 1Department of Gynecologic Oncology, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Municipal Key Clinical Specialty, Shanghai Key Laboratory of Embryo Original Disease, Shanghai, 200030, People’s Republic of China; 2Department of Obstetrics and Gynecology, Guangzhou Women and Children’s Medical Centre, Guangzhou 510623, People’s Republic of China; 3Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Major Obstetric Diseases of Guangdong Province, Guangzhou 510150, People’s Republic of China; 4Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People’s Republic of China; 5Department of Obstetrics and Gynecology, Women and Children’s Hospital of Ningbo City, Ningbo 315012, People’s Republic of China; 6Department of Gynecology, Affiliated Hospital of Jining Medical University, Jining 272029, People’s Republic of China; 7Department of Gynecology, Women and Children’s Hospital of Qingdao, Qingdao 266000, People’s Republic of China; 8Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun 130000, People’s Republic of China; 9Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated of China Medical University, Shenyang 110004, People’s Republic of China; 10Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People’s Republic of China; 11Department of Obstetrics and Gynecology, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou 350001, People’s Republic of China; 12Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, People’s Republic of ChinaCorrespondence: Yudong Wang Department of Gynecologic OncologyInternational Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, NO. 1961, Huashan Road, Shanghai 200030, People’s Republic of ChinaEmail gfywangyudong@126.comJiandong WangDepartment of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, NO. 251, Yao Jiayuan Road, Beijing 100026, People’s Republic of ChinaEmail wangjiandongxy@hotmail.comPurpose: The aim of this study was to investigate the clinical characteristics and management of malignant ovarian tumors during pregnancy, as well as the feto-maternal outcomes and analyze the influential factors on the pregnancy outcomes.Patients and Methods: Eighty-five patients with ovarian malignancies during pregnancy treated at 12 tertiary hospitals between 2009 and 2019 were analyzed in this study. The clinical features, histopathological characteristics, clinical management, and maternal and perinatal outcomes were retrospectively analyzed. The clinical features and managements were compared between abortion group and live birth group.Results: The following diagnoses were made: 41 (48.24%) patients with borderline ovarian tumors, 18 (21.18%) patients with epithelial ovarian cancers, 17 (20.00%) patients with non-epithelial ovarian malignancies and 9 (10.59%) patients with metastatic ovarian tumors. Thirty-six (42.45%) patients underwent conservative surgical treatment. Thirty-four (40.00%) patients opted for fertility-sparing surgery, and fifteen (17.56%) patients received radical surgery. Chemotherapy was administered to 32.94% of the patients. The proportion of ovarian malignancies diagnosed in the first trimester in the abortion group was higher than that in the live birth group (P< 0.05). However, tumor diameter, reproductive history, stage and surgical indications showed no significant differences between groups. A total of 67 live babies were recorded in this study, including 19 premature babies and 1 full-term newborn who died of respiratory distress. All of the BOTs were diagnosed with stage I, among whom 38 (92.68%) patients exhibited disease-free survival. Twenty-eight ovarian cancers were in stage I–II and 26 of them had disease-free survival with the longest follow-up time of 10 years. Five of the sixteen patients in advanced stage (stage III–IV) died, four of whom had metastatic tumors.Conclusion: Pregnant women with early-stage malignant ovarian tumors appear to have favorable outcomes. Conservative surgery is acceptable for early-stage borderline ovarian tumors during pregnancy. The gestational age of ovarian malignancy detection is key for pregnancy outcomes.Keywords: malignant ovarian tumor, pregnancy, management, prognosishttps://www.dovepress.com/malignant-ovarian-tumors-during-pregnancy-a-multicenter-retrospective--peer-reviewed-article-CMARmalignant ovarian tumorpregnancymanagementprognosis